{
  "trial_id": "NCT00312598",
  "overall_assessment": "likely_ineligible",
  "inclusion": [
    {
      "criterion": "Any ethnicity",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "Antipsychotic monotherapy with olanzapine, risperidone or quetiapine for minimum of 1 month at entry into study and with weight gain of 2 BMI units while on this medication",
      "label": "not_met",
      "evidence": "unknown"
    },
    {
      "criterion": "Antipsychotic monotherapy with aripiprazole is planned by the subject's treating psychiatrist",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "Subjects able to fully participate in the informed consent process",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "Female subjects of childbearing potential must be using a medically accepted means of contraception which includes tubal ligation, hysterectomy, condoms, oral contraceptives, intrauterine device (IUD), cervical cap, diaphragm, transdermal contraceptive patch, and abstinence",
      "label": "not_met",
      "evidence": "unknown"
    }
  ],
  "exclusion": [
    {
      "criterion": "Subjects have had a previous trial of aripiprazole",
      "label": "met",
      "evidence": "unknown"
    },
    {
      "criterion": "Serious or unstable medical illness which requires ongoing treatment with medication",
      "label": "met",
      "evidence": "unknown"
    }
  ],
  "notes": "Patient has serious or unstable medical illness (CHF, dCHF) requiring ongoing treatment with medication.",
  "_meta": {
    "topic_id": "14",
    "trial_id": "NCT00312598",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}